Genmab — Maj 2026
-
Genmab A/S (GMAB) Q1 2026 earnings call transcript https://finance.yahoo.com/quote/GMAB/earnings/GMAB-Q1-2026-earnings_call-419930.html
-
Genmab i stort fald efter regnskab: Usikkerhed omkring udvidet studie kan være årsag mener analytiker https://proinvestor.com/investornyt/1442177/genmab-i-stort-fald-efter-regnskab-usikkerhed-omkring-udvidet-studie-kan-vaere-arsag-mener-analytiker
-
Stockwatch DK
@StockwatchDK
$GMABWilliam Blair analyst Matt Phipps maintains his Buy rating og Genmab due to a combination of factors tied to Genmab’s near‑term catalysts and solid execution. https://x.com/StockwatchDK/status/2052694645826531435
-
Merus-opkøbet blev annonceret 29. september 2025.
Due diligence-processen foregik primært i sommeren og efteråret 2025 (før og umiddelbart efter annonceringen).
Opkøbet blev afsluttet 12. december 2025.Tahi Ahmadi sagde på Q1 2026 earnings call (7. maj 2026), at beslutningen om at udvide LiGeR-HN1-studiet blev truffet på baggrund af indsigter fra due diligence-processen efter/op i forbindelse med Merus-opkøbet.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind